SecBot SecBot

CRSP drug pipeline

CRISPR Therapeutics AG · 4 rated drugs
$40.86
+1.2% 1-day · Nov 17
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
4
4 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially launched (FDA approval December 2023)

CASGEVY exagamglogene autotemcel Updated Aug 27

What to watch

Watch quarterly CASGEVY revenue trends as the key value driver, Q3 2026 results (~Nov 2026) will show whether the 151% YoY growth rate is sustainable. The 19.4% short interest and 15.6 days to cover create squeeze potential on positive commercial surprises, but the lack of a near-term binary catalyst limits near-term trading conviction. The analyst mean target of $87.56 implies ~48% upside from current levels.

Bull case
  • CASGEVY is the first-ever FDA-approved CRISPR-based therapy, a landmark scientific and commercial asset with no direct CRISPR-based competitor
  • Q2 2026 CASGEVY revenue reached $76M (+151% YoY), showing accelerating commercial adoption and growing patient uptake
  • FDA label expansion to children aged 2+ opens a meaningful additional patient population
Bear case
  • CASGEVY is a complex, expensive cell therapy requiring bone marrow conditioning (chemotherapy), limiting patient willingness and physician adoption
  • Vertex Pharmaceuticals books all CASGEVY revenue; CRISPR's ~40% profit share is netted as collaboration expense, reducing top-line transparency
  • Competition from bluebird bio's Lyfgenia (approved gene therapy for SCD) and emerging alternatives could pressure market share
● neutral
Impact
PhasePreclinical (IND-enabling)
Time to marketUnknown — at least 3-5 years if clinical trials succeed. The drug is still preclinical with no IND filed.

CTX213 Updated Aug 27

What to watch

CTX213 is too early-stage to drive near-term CRSP stock movement. Investors should focus on CRISPR Therapeutics' nearer-term catalysts: CASGEVY commercial ramp, Phase 1/2 data for CTX310 (hypertriglyceridemia) and zugo-cel (autoimmune), and any IND filing announcement for CTX213. The diabetes program is a long-duration call option, not a near-term trading catalyst.

Bull case
  • CTX213 addresses a massive market: the global Type 1 diabetes population (~8-10 million) who currently require lifelong insulin therapy.
  • The 'deviceless' approach eliminates the encapsulation device, potentially simplifying manufacturing and administration vs. predecessor CTX211.
  • CRISPR Therapeutics has a non-exclusive IP license deal with Vertex for hypoimmune cell therapies in T1D, providing potential milestone/royalty income.
Bear case
  • CTX213 is preclinical with no IND filed, it may never enter or succeed in human trials; most preclinical drug candidates fail.
  • Vertex (a much larger competitor) opted out of the CRISPR diabetes collaboration in 2024 and is developing its own islet cell therapies (VX-880), creating a formidable competitive threat.
  • The predecessor CTX211's Phase 1/2 trial was terminated, raising questions about the underlying technology.
● neutral
Impact
PhaseUnknown — no clinical trials or regulatory filings found for CTX310.
Time to marketUnknown — no clinical data or development timeline has been publicly disclosed for CTX310.

CTX310 Updated Aug 27

What to watch

CTX310 does not appear in any public database, clinical trial registry, SEC filing, or press release as of this report. Investors should verify the drug name and check CRISPR Therapeutics' official pipeline page or recent corporate presentations for any mention before taking a position. The company's key approved product is CASGEVY (CTX001), and its most advanced clinical-stage asset is CTX131.

Bull case
  • CRISPR Therapeutics (CRSP) is a well-funded, Nasdaq-listed gene-editing pioneer with one approved product (CASGEVY/CTX001) and a deep pipeline.
  • The company has a strong analyst consensus with 17 Buy/Strong Buy ratings vs 0 Sell, and a mean price target of $87.56 (34.7% upside from ~$60.90).
  • If CTX310 is a real preclinical program, it would benefit from CRISPR Therapeutics' established gene-editing platform and manufacturing expertise.
Bear case
  • No evidence of CTX310 exists in any public database, clinical trial registry, or SEC filing, the drug may not be a real or active program.
  • CRISPR Therapeutics has a broad pipeline but no CTX310 program has been disclosed; if it exists it is likely preclinical with no near-term catalyst.
  • CRSP stock has a high short-volume ratio (60-73% in late July 2026), indicating significant bearish positioning.
● neutral
Impact
PhaseNot stated
Time to marketNot stated

CTX340 Updated Aug 27

What to watch

CTX340 cannot be found in any public database, investors should not trade CRSP based on this drug name until the company explicitly discloses a program by this designation. For CRISPR Therapeutics as a whole, the key near-term value drivers are CASGEVY commercial ramp (Q2 2026 revenue $76M, +151% YoY) and any data readouts from the CTX131 Phase 2 CAR-T program, not an unidentifiable CTX340.

Bull case
  • CRISPR Therapeutics has a validated platform with the approved drug CASGEVY (CTX001), demonstrating its ability to bring gene-editing therapies to market, any new pipeline candidate benefits from this infrastructure.
  • The company reported Q2 2026 CASGEVY revenue of $76M (+151% YoY) and beat consensus EPS estimates, indicating strong commercial execution that could fund pipeline expansion.
Bear case
  • CTX340 is not referenced in any clinical trial, FDA filing, press release, or SEC document in available databases, it may be a preclinical program years away from human testing, or the name may be incorrect/mistyped.
  • CRISPR Therapeutics faces significant competition in the gene-editing space from companies like Vertex (VRTX), Intellia (NTLA), Editas (EDIT), and Beam (BEAM), any of which could have overlapping pipeline programs.
  • With no publicly disclosed data on CTX340, there is no basis to evaluate its therapeutic potential, safety, or market opportunity.

Other drugs in filings and trials

no drug report yet

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
CTX131A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic MalignanciesPhase 2Completed12Mar 11, 2026